Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 16.2%, or 44c, after results are released. Median move over the past eight quarters is 2.6%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Largest borrow rate increases among liquid names
- INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
- INmune Bio options imply 14.9% move in share price post-earnings
- INmune Bio Releases Video on Alzheimer’s Trial Results
- INmune Bio announces video detailing findings from Phase 2 MINDFuL trial